论文部分内容阅读
我们已报道重组大鼠ＩＬ－３和小鼠ＧＭ－ＣｓＦ对ＬＴ１２白血病细胞的增殖有不同程度的抑制活性。本研究发现重组人ＩＬ－６在１０００～５０００Ｕ／ｍｌ呈剂量依赖性抑制ＬＴＩ２白血病祖细胞集落形成及ＤＮＡ合成。５０００Ｕ／ｍｌ对ＣＦＵ－Ｌ的抑制率达５２．９％，而对ＤＮＡ合成则为４１．３％，此外，ＩＬ－６还明显增加ＩＬ－３和ＧＭ－ＣＳＦ对ＬＴ１２细胞的抑制活性，对ＣＦＵ－Ｌ的抑制强弱依次为ＩＬ－６＋ＧＭ－ＣＳＦ、ＩＬ－３＋ＧＭ－ＣＳＦ、及ＩＬ－６＋ＩＬ－３，ＩＬ－６＋ＩＬ－３＋ＧＭ－ＣＳＦ三因子的结合并不能增加抑制效应；对ＤＮＡ合成的抑制作用为ＩＬ－６＋ＩＬ－３＋ＧＭ－ＣＳＦ＞ＩＬ－６＋ＧＭ－ＣＳＦ＞ＩＬ－３＋ＧＭ－ＣＳＦ＞ＩＬ－６＋ＩＬ－３。提示上述造血因子除刺激正常造血外，在白血病的治疗中可能具有一定意义。
We have reported that recombinant rat IL-3 and mouse GM-CsF have different degrees of inhibitory activity against proliferation of LT12 leukemia cells. This study found that recombinant human IL-6 inhibited the colony formation and DNA synthesis of LTI2 leukemia progenitor cells in a dose-dependent manner from 1000 to 5000 U/ml. The inhibition rate of 5000U/ml against CFU-L was 52.9%, while that against DNA synthesis was 41.3%. In addition, IL-6 also significantly increased the inhibitory activity of IL-3 and GM-CSF on LT12 cells. The inhibition of CFU-L was IL-6+GM-CSF, IL-3+GM-CSF, and IL-6+IL-3. The combination of the three factors IL-6+IL-3+GM-CSF did not increase the inhibitory effect; DNA synthesis was inhibited. The effect was IL-6+IL-3+GM-CSF>IL-6+GM-CSF>IL-3+GM-CSF>IL-6+IL-3. It is suggested that the above hematopoietic factors may have some significance in the treatment of leukemia besides stimulating normal hematopoiesis.